T. Virtanen , A , Haikarainen , T , Raivola , J & Silvennoinen , O 2019 , ' Selective JAKinibs : Prospects in Inflammatory and Autoimmune Diseases ' , BioDrugs , vol. 33 , no. 1 , pp. 15-32 . https://doi.org/10.1007/s40259-019-00333-w
Title: | Selective JAKinibs : Prospects in Inflammatory and Autoimmune Diseases |
Author: | T. Virtanen, Anniina; Haikarainen, Teemu; Raivola, Juuli; Silvennoinen, Olli |
Contributor organization: | Institute of Biotechnology |
Date: | 2019-02 |
Language: | eng |
Number of pages: | 18 |
Belongs to series: | BioDrugs |
ISSN: | 1179-190X |
DOI: | https://doi.org/10.1007/s40259-019-00333-w |
URI: | http://hdl.handle.net/10138/305060 |
Abstract: | Cytokines, many of which signal through the JAK–STAT (Janus kinase–Signal Transducers and Activators of Transcription) pathway, play a central role in the pathogenesis of inflammatory and autoimmune diseases. Currently three JAK inhibitors have been approved for clinical use in USA and/or Europe: tofacitinib for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis, baricitinib for rheumatoid arthritis, and ruxolitinib for myeloproliferative neoplasms. The clinical JAK inhibitors target multiple JAKs at high potency and current research has focused on more selective JAK inhibitors, almost a dozen of which currently are being evaluated in clinical trials. In this narrative review, we summarize the status of the pan-JAK and selective JAK inhibitors approved or in clinical trials, and discuss the rationale for selective targeting of JAKs in inflammatory and autoimmune diseases. |
Subject: |
1182 Biochemistry, cell and molecular biology
JANUS KINASE INHIBITOR ACTIVE RHEUMATOID-ARTHRITIS SYSTEMIC-LUPUS-ERYTHEMATOSUS MODIFYING ANTIRHEUMATIC DRUG NATURAL-KILLER-CELLS DOUBLE-BLIND INADEQUATE RESPONSE VX-509 DECERNOTINIB ANKYLOSING-SPONDYLITIS JAK1 INHIBITOR |
Peer reviewed: | Yes |
Rights: | cc_by |
Usage restriction: | openAccess |
Self-archived version: | publishedVersion |
Total number of downloads: Loading...
Files | Size | Format | View |
---|---|---|---|
Virtanen2019_Ar ... eJAKinibsProspectsInIn.pdf | 2.271Mb |
View/ |